Using AAV vectors expressing the β 2 -adrenoceptor or associated Gα proteins to modulate skeletal muscle mass and muscle fibre size

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Hagg, Adam ^a,b   Colgan, Timothy D ^a,b   Thomson, Rachel E ^a   Qian, Hongwei ^a   Lynch, Gordon S ^b   Gregorevic, Paul ^a,b,c,d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL FUMARATE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MYOSIN II; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL; C57BL MOUSE; DEPENDOPARVOVIRUS; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENE TRANSFER; GENE VECTOR; GENETICS; HYPERTROPHY; KNOCKOUT MOUSE; MALE; METABOLISM; ORGAN SIZE; PATHOLOGY; SKELETAL MUSCLE; SKELETAL MUSCLE CELL; WESTERN BLOTTING;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; BLOTTING, WESTERN; DEPENDOVIRUS; FORMOTEROL FUMARATE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GTP-BINDING PROTEIN ALPHA SUBUNIT, GI2; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HYPERTROPHY; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MYOSIN TYPE II; ORGAN SIZE; RECEPTORS, ADRENERGIC, BETA-2;

EID: 84961116320     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23042     Document Type: Article

References (45)

1. Premont, R. T. & Gainetdinov, R. R. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu. Rev. Physiol. 69, 511-534 (2007).
2. Dror, R. O. et al. Activation mechanism of the β2-adrenergic receptor. Proc. Natl. Acad. Sci. USA 108, 18684-18689 (2011).
3. Ryall, J. G., Church, J. E. & Lynch, G. S. Novel role for β -adrenergic signalling in skeletal muscle growth, development and regeneration. Clin. Exp. Pharmacol. Physiol. 37, 397-401 (2010).
4. Daaka, Y., Luttrell, L. M. & Lefkowitz, R. J. Switching of the coupling of the β 2-adrenergic receptor to different G proteins by protein kinase A. Nature 390, 88-91 (1997).
5. Pearen, M. A., Ryall, J. G., Lynch, G. S. & Muscat, G. E. Expression profiling of skeletal muscle following acute and chronic β 2-adrenergic stimulation: implications for hypertrophy, metabolism and circadian rhythm. BMC Genomics 10, 448 (2009).
6. Ryall, J. G., Plant, D. R., Gregorevic, P., Sillence, M. N. & Lynch, G. S. β 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. J. Physiol. (Lond.) 555, 175-188 (2004).
7. Toledo, M. et al. Formoterol in the treatment of experimental cancer cachexia: effects on heart function. J. Cachexia Sarcopenia Muscle 5, 315-320 (2014).
8. Rommel, C. et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3, 1009-1013 (2001).
9. Kline, W. O., Panaro, F. J., Yang, H. & Bodine, S. C. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. J. Appl. Physiol. 102, 740-747 (2007).
10. Goncalves, D. A. et al. Mechanisms involved in 3, 5-cyclic adenosine monophosphate-mediated inhibition of the ubiquitinproteasome system in skeletal muscle. Endocrinology 150, 5395-5404 (2009).
11. Joassard, O. R. et al. Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-lysosome pathways in response to formoterol administration in rat skeletal muscle. Int. J. Biochem. Cell Biol. 45, 2444-2455 (2013).
12. Koopman, R. et al. Cellular mechanisms underlying temporal changes in skeletal muscle protein synthesis and breakdown during chronic β -adrenoceptor stimulation in mice. J. Physiol. (Lond.) 588, 4811-4823 (2010).
13. Maltin, C. A. et al. Inhibition and reversal of denervation-induced atrophy by the β -agonist growth promoter, clenbuterol. Biosci. Rep. 6, 811-818 (1986).
14. Jiang, G. L. et al. Randomized, double-blind, and placebo-controlled trial of clenbuterol in denervated muscle atrophy. ISRN Pharmaceut. 2011, 981254 (2011).
15. Harcourt, L. J., Schertzer, J. D., Ryall, J. G. & Lynch, G. S. Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue. Neuromus. Dis. 17, 47-55 (2007).
16. Kissel, J. T. et al. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology 50, 1402-1406 (1998).
17. Skura, C. L., Fowler, E. G., Wetzel, G. T., Graves, M. & Spencer, M. J. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology 70, 137-143 (2008).
18. Ryall, J. G., Schertzer, J. D. & Lynch, G. S. Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia. J. Gerontol. A. Biol. Sci. Med. Sci. 62, 813-823 (2007).
19. Costelli, P. et al. Muscle protein waste in tumor-bearing rats is effectively antagonized by a β 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J. Clin. Invest. 95, 2367-2372 (1995).
20. Greig, C. A. et al. Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy. Support. Care Cancer 22, 1269-1275 (2014).
21. Blankinship, M. J. et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol. Ther. 10, 671-678 (2004).
22. Gregorevic, P. et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10, 828-834 (2004).
23. Mendell, J. R. et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol. Ther. 23, 192-201 (2015).
24. Buchlis, G. et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 119, 3038-3041 (2012).
25. Goodman, C. A. et al. Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique. FASEB J. 25, 1028-1039 (2011).
26. Linglart, A. et al. Coding GNAS mutations leading to hormone resistance impair in vitro agonist-and cholera toxin-induced adenosine cyclic 3, 5-monophosphate formation mediated by human XLα s. Endocrinology 147, 2253-2262 (2006).
27. Mariot, V. et al. Potent constitutive cyclic AMP-generating activity of XLα s implicates this imprinted GNAS product in the pathogenesis of McCune-Albright syndrome and fibrous dysplasia of bone. Bone 48, 312-320 (2011).
28. Church, J. E. et al. Functional β -adrenoceptors are important for early muscle regeneration in mice through effects on myoblast proliferation and differentiation. PLoS One 9, e101379 (2014).
29. Rohrer, D. K., Chruscinski, A., Schauble, E. H., Bernstein, D. & Kobilka, B. K. Cardiovascular and metabolic alterations in mice lacking both beta1-and beta2-adrenergic receptors. J. Biol. Chem. 274, 16701-16708 (1999).
30. Burniston, J. G. et al. Myotoxic effects of clenbuterol in the rat heart and soleus muscle. J. Appl. Physiol. 93, 1824-1832 (2002).
31. Duncan, N. D., Williams, D. A. & Lynch, G. S. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin. Sci. 98, 339-347 (2000).
32. Gregorevic, P., Ryall, J. G., Plant, D. R., Sillence, M. N. & Lynch, G. S. Chronic β -agonist administration affects cardiac function of adult but not old rats, independent of β -adrenoceptor density. Am. J. Physiol. Heart Circ. Physiol. 289, H344-349 (2005).
33. Brown, B. D. et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol. 25, 1457-1467 (2007).
34. Salva, M. Z. et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol. Ther. 15, 320-329 (2007).
35. Minetti, G. C. et al. Gα i2 signaling promotes skeletal muscle hypertrophy, myoblast differentiation, and muscle regeneration. Sci. Signaling 4, ra80 (2011).
36. Chen, M. et al. Gsα deficiency in skeletal muscle leads to reduced muscle mass, fiber-type switching, and glucose intolerance without insulin resistance or deficiency. Am. J. Physiol. Cell Physiol. 296, C930-940 (2009).
37. Minetti, G. C. et al. Gα i2 signaling is required for skeletal muscle growth, regeneration, and satellite cell proliferation and differentiation. Mol. Cell. Biol. 34, 619-630 (2014).
38. Rudolph, U. et al. Ulcerative colitis and adenocarcinoma of the colon in Gα i2-deficient mice. Nat. Genet. 10, 143-150. (1995).
39. Weinstein, L. S., Xie, T., Zhang, Q. H. & Chen, M. Studies of the regulation and function of the Gsα gene Gnas using gene targeting technology. Pharmacol. Ther. 115, 271-291 (2007).
40. Hinkle, R. T. et al. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the β 2-adrenergic receptor. Muscle Nerve 25, 729-734 (2002).
41. von Maltzahn, J., Bentzinger, C. F. & Rudnicki, M. A. Wnt7a-Fzd7 signalling directly activates the Akt/mTOR anabolic growth pathway in skeletal muscle. Nat. Cell Biol. 14, 186-191 (2012).
42. He, Q., Zhu, Y., Corbin, B. A., Plagge, A. & Bastepe, M. The G protein α subunit variant XLα s promotes inositol 1, 4, 5-trisphosphate signaling and mediates the renal actions of parathyroid hormone in vivo. Sci Signal 8, ra84 (2015).
43. Kimura, S. & Yoshioka, K. Parathyroid hormone and parathyroid hormone type-1 receptor accelerate myocyte differentiation. Sci. Rep. 4, 5066 (2014).
44. Winbanks, C. E. et al. TGF-β regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J. Biol. Chem. 286, 13805-13814 (2011).
45. Johnston, A. J. et al. Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival. Cell 162, 1365-1378 (2015).